Skip to main content

Advertisement

Figure 5 | Breast Cancer Research

Figure 5

From: QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

Figure 5

Levels of P-AKT were measured in LCC6, LCC6Her2, MCF-7, and MCF-7Her2 cells after treatment with a singles dose of QLT0267, docetaxel, or a combination of QLT0267 and docetaxel. (a) LCC6, LCC6Her2, MCF-7, and MCF-7Her2 cells express baseline levels of integrin-linked kinase (ILK), protein kinase B (AKT), and phosphorylated AKT (P-AKT). (b) LCC6, (c) LCC6Her2, (d) MCF-7, and (e) MCF-7Her2 cells were treated for eight hours QLT0267 (267) (42 μM), docetaxel (Dt) (1 nM), or the combination of 267 and Dt. Western blot analysis using a fluorescence based imaging system (odyssey, Licor) shows that treatment with 267 and 267/Dt elicit considerable reductions in the level of P-AKT relative to controls (untreated cells). Treatment with Dt had no effect on P-AKT levels. Reductions in P-AKT were not attributable to changes in the level of ILK or AKT. Band intensities for P-AKT were normalized to actin then to untreated controls and changes in levels are indicated in the values provided just below the P-AKT band (n = 3).

Back to article page